title: [SYSTEMIC INFLAMMATION AND COMPROMISED INTESTINAL BARRIER DURING SUCCESSFUL TREATMENT OF HIV INFECTION].
abstract: The relationship between immunity disorders, destruction of intestinal barrier and development of systemic inflammation during antiviral therapy in patients with HIV infection is a topical issue in terms of suppression of virus replication and reduction of its role in the pathological process.
  
  
  OBJECTIVE
  Blood of HIV-infected patients given antiretroviral therapy (n = 21) and non-infected volunteers (n = 20).
  
  
  METHODS
  Identification of cells among CD4⁺ and CD8⁺ T-lymphocytes expressing markers of activation (CD38, HLA-DR), depletion (PD-1), and interleukin (IL) 7 receptor (CD127); measurement of blood levels of IL-6, neopterin, soluble CD14 (sCD14), intestinal fatty acid-binding peptide (I-FABP), and bacterial lipopolysaccharide. Correlation analysis of the dependence between cell immunity and systemic inflammation was performed.
  
  
  RESULTS
  HIV-infected patients had more activated CD4⁺ and CD8⁺ T-lymphocytes and CD4⁺ T-cells expressing PD-1 marker than non-infected subjects but less CD4⁺ and CD8+ T-lymphocytes expressing CD127. Blood IL-6, neopterin, soluble CD14, I-FABP and bacterial lipopolysaccharide levels in the former were higher than in the latter HIV-infected patients showed significant correlation of cell immunity parameters with blood neopterin and FABP levels.
  
  
  CONCLUSIONS
  The process of activation, depletion, and regeneration of T-lymphocytes in. HIV infection are related to the destruction of intestinal barrier and systemic macrophage activation.
authors.forename: N G
authors.initials: NG
authors.lastname: Shmagel
authors.forename: K V
authors.initials: KV
authors.lastname: Shmagel
authors.forename: L B
authors.initials: LB
authors.lastname: Korolevskaya
authors.forename: E V
authors.initials: EV
authors.lastname: Saidakova
authors.forename: V A
authors.initials: VA
authors.lastname: Chereshnev
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000097:blood; D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006678:HIV / Q000187:drug effects / Q000502:physiology; D015658:HIV Infections / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D006684:HLA-DR Antigens / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000276:immunology / Q000503:physiopathology; D053699:Interleukin-7 Receptor alpha Subunit / Q000097:blood; D007413:Intestinal Mucosa / Q000503:physiopathology*; D008262:Macrophage Activation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013223:Statistics as Topic; D014779:Virus Replication / Q000187:drug effects
chemical_list: D044966:Anti-Retroviral Agents; D015415:Biomarkers; D006684:HLA-DR Antigens; D053699:Interleukin-7 Receptor alpha Subunit; D051997:ADP-ribosyl Cyclase 1